# Altimmune, Inc. (ALT) Stock Analysis: Unpacking a Potential 497% Upside in the Biotech Sector

- Link: https://www.directorstalkinterviews.com/altimmune-inc-alt-stock-analysis-unpacking-a-potential-497-upside-in-the-biotech-sector/4121250971
- Published: 2026-05-08T10:17:19+01:00
- Author: Madison Wilson

Altimmune, Inc. (NASDAQ: ALT), a promising player in the biotechnology sector, has
caught the attention of investors with a striking potential upside of 497.04%. Based
in Gaithersburg, Maryland, Altimmune is a late clinical stage biopharmaceutical 
company focusing on innovative therapies for critical liver diseases. At the forefront
is their lead product candidate, pemvidutide, currently progressing through Phase
3 clinical trials, targeting metabolic dysfunction-associated steatohepatitis and
alcohol-related liver conditions.

Trading at $3.04 per share, Altimmune’s stock has experienced a slight dip of 0.07%
recently, but it remains within the 52-week range of $2.60 to $7.71. The company’s
market capitalization stands at $590.84 million, reflecting its significant position
in the healthcare sector. Despite the drop, the stock’s potential upside remains
an enticing prospect for investors seeking high-growth opportunities.

Valuation metrics for Altimmune reveal some challenges typical for biotechnology
firms in this phase. With a Forward P/E of -2.30 and a lack of trailing P/E, PEG,
and Price/Book ratios, the company is yet to transition into profitability. However,
these metrics underscore the speculative nature of investing in biotech stocks, 
where future growth potential often outweighs current earnings.

Altimmune’s performance metrics further highlight the high-risk, high-reward scenario.
The company boasts an impressive revenue growth rate of 420.00%, suggesting a robust
pipeline and promising market potential. Yet, it grapples with a net income that
remains undisclosed and an EPS of -1.00, reflecting ongoing investments in their
product development. Return on equity stands at -50.57%, indicative of the high 
costs involved in advancing clinical trials. Additionally, a negative free cash 
flow of -$38,722,124 underscores the company’s significant financial commitments
as it advances its research endeavors.

Despite these challenges, Altimmune’s dividend information aligns with its growth
trajectory, with no dividend yield and a payout ratio of 0.00%. This approach is
typical for companies focused on reinvesting earnings into research and development
rather than distributing profits to shareholders.

Analyst sentiment around Altimmune is notably bullish, with nine buy ratings and
two hold ratings, and no sell recommendations. The target price range spans from
$2.50 to an optimistic $28.00, with an average target price of $18.15. This optimism
is largely fueled by the company’s innovative pipeline and the potential market 
impact of pemvidutide.

Technical indicators provide further insights into Altimmune’s stock performance.
Currently, the stock is trading below both its 50-day and 200-day moving averages,
which are at $3.38 and $4.01, respectively. The RSI (14) of 46.18 suggests a neutral
stance, while the MACD of -0.13 and a signal line of -0.16 indicate potential volatility.

For investors considering Altimmune, the stock presents a classic biotech investment
profile: high risk with the potential for high reward. The company’s focus on groundbreaking
therapies for serious liver diseases, combined with a significant potential upside,
makes it a compelling candidate for those with an appetite for speculative growth
opportunities. However, it’s crucial for investors to weigh the inherent risks associated
with clinical trials and regulatory approvals that could significantly impact the
stock’s trajectory.

Share on: